Literature DB >> 6836645

Human pial vascular reactions to intravenous Nimodipine-infusion during EC-IC bypass surgery.

L M Auer, R W Oberbauer, H V Schalk.   

Abstract

In previous experimental work, the Ca-antagonist Nimodipine had shown a predominantly cerebroarterial dilatory effect. In the present double-blind study of 16 patients, pial arterial and venous reaction was investigated during EC-IC bypass surgery, infusing 1 microgram kg-1min-1 of Nimodipine intravenously. In pial arteries with resting diameters between 25 and 70 micrometers, a significant 18% dilatation was observed. Results are considered promising for future trials in the treatment and prevention of cerebral ischemia caused by vasoconstriction or vasospasm, especially vasospasm following subarachnoid hemorrhage.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6836645     DOI： 10.1161/01.str.14.2.210

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


  12 in total

Review 1.  Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine.

Authors:  B Ljunggren; L Brandt; H Säveland; B Romner; T Ryman; K E Andersson
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

2.  Intraoperative use of laser Doppler in the study of cerebral microvascular circulation.

Authors:  V A Fasano; R Urciuoli; P Bolognese; M Mostert
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage.

Authors:  D Tettenborn; L Porto; T Ryman; V Strugo; G Taquoi; R Battye
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

4.  Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine.

Authors:  J Philippon; R Grob; F Dagreou; M Guggiari; M Rivierez; P Viars
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

5.  [Effect of the Ca antagonist nimodipine on global and regional cerebrovascular circulation].

Authors:  M R Gaab; C P Rode; E H Schakel; I Haubitz; J Bockhorn; A Brawanski
Journal:  Klin Wochenschr       Date:  1985-01-02

Review 6.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Acute surgery of cerebral aneurysms and prevention of symptomatic vasospasm.

Authors:  L M Auer
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

8.  Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study.

Authors:  R W Seiler; P Grolimund; H R Zurbruegg
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

Review 9.  Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

10.  Nimodipine and early aneurysm operation in good condition SAH patients.

Authors:  L M Auer; L Brandt; U Ebeling; J Gilsbach; U Groeger; A Harders; B Ljunggren; F Oppel; H J Reulen; H Saeveland
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.